Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of AOD-9604 and Semaglutide — mechanism, dosing, side effects, legal status, and pricing.
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) originally developed as an anti-obesity agent. It stimulates lipolysis and inhibits lipogenesis without the diabetogenic or growth-promoting effects of full HGH.
Semaglutide is an FDA-approved GLP-1 receptor agonist used to treat type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It has become one of the most widely prescribed medications for obesity due to its significant weight-loss efficacy.
AOD-9604
Semaglutide
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
Phase 2 clinical trials showed modest weight loss in obese subjects over 12 weeks. Preclinical studies demonstrate significant fat reduction without affecting lean mass or glucose homeostasis. It has FDA GRAS (Generally Recognized As Safe) status for food use.
The STEP clinical trial program demonstrated average weight loss of 15–17% body weight over 68 weeks. The SELECT trial showed a 20% reduction in major adverse cardiovascular events. Oral semaglutide (Rybelsus) is also FDA-approved for type 2 diabetes.
AOD-9604 and Semaglutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs